Purchase of Shares by PDMR

RNS Number : 4773Z

The MedicX Fund Limited

15 December 2017

 

For immediate release

15 December 2017

MedicX Fund Limited

("MedicX Fund", "the Fund" or "the Company")

Purchase of Shares by PDMR

The Company announces that it has received notification that on 14 December 2017, John Hearle, Director and a Person Discharging Managerial Responsibilities ("PDMR") of the Company purchased 11,870 Ordinary Shares in the Company.

The following notifications, which have been made in accordance with the requirements of the EU Market Abuse Regulations, provide further detail:

1.	Details of PDMR
a)	Name	John Hearle
2.	Reason for Notification Purchase of shares
a)	Position/status	Director
b)	Initial notification/ amendment	Initial notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	MedicX Fund Limited
b)	LEI	2138008POF35FTNFCB25
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument Identification code	Ordinary shares of no par value GG00B1DVQL92
b)	Nature of the transaction	Purchase of 11,870 shares
c)	Price(s) and volume(s)	Price(s) Volume(s) 84.25p 11,870
d)	Aggregated Information	N/A single transaction
e)	Date of the transaction	14 December 2017
f)	Place of the transaction	London Stock Exchange, Main Market (XLON)
g)	Other information	Following the transaction, John Hearle holds 43,869 shares in the Company

End

For further information please contact:

MedicX Fund                                                                  [phone]

David Staples, Chairman

Octopus Healthcare Group                                               [phone]

Mike Adams, Chief Executive Officer

Buchanan                                                                        [phone]

Charles Ryland/Victoria Hayns

Information on MedicX Fund Limited

MedicX Fund Limited (the "Fund" or the "Company", or together with its subsidiaries, the "Group") is the specialist primary care infrastructure investor in modern, purpose-built primary healthcare properties in the United Kingdom and Ireland, listed on the London Stock Exchange, with a portfolio comprising 152 properties.

The Investment Adviser to the Company is Octopus Healthcare Adviser Ltd, which is part of the Octopus Healthcare group. Octopus Healthcare invests in and develops properties as well as creating partnerships to deliver innovative healthcare buildings to improve the health, wealth and wellbeing of the UK. It currently manages over £1.2 billion of healthcare investments across a number of platforms, with a focus on five core areas: GP surgeries, care homes, special education schools, retirement housing and private hospitals. Octopus Healthcare is part of the Octopus group, a fast-growing UK fund management business with leading positions in several specialist sectors including healthcare property, energy, property finance and smaller company investing. Octopus manages £7 billion of funds for more than 50,000 retail and institutional investors as well as supplying energy to more than 100,000 customers

Octopus Healthcare Adviser Ltd is authorised and regulated by the Financial Conduct Authority.

The Company's website address is www.medicxfund.com.  Neither the contents of the Company's website nor the contents of any website accessible from hyperlinks on the Company's website (or any other website), nor the contents of any website accessible from hyperlinks within this announcement, are incorporated into, or forms part of, this announcement.

The Company's Legal Entity Identifier is 2138008POF35FTNFCB25

 

END

 

 

DSHVELBFDLFXFBE